GT Biopharma regains Nasdaq compliance for independent director and audit committee rules

GT Biopharma, Inc.

Received Nasdaq Staff letter on Dec 22, 2021 confirming compliance with Listing Rule 5605(b)(1).
Prior non-compliance stemmed from Michael Breen's appointment as Executive Chairman on Nov 8, 2021.
Nasdaq had notified the company of the deficiency on Nov 23, 2021.
Compliance restored following resignation of director Anthony Cataldo effective Dec 15, 2021; matter closed.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.